These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 32234757

  • 1. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A.
    Clin Cancer Res; 2020 Jul 15; 26(14):3641-3648. PubMed ID: 32234757
    [Abstract] [Full Text] [Related]

  • 2. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
    Sun X, Song H, Sun X, Liao C, Wang G, Xu Y, Li L, Han Y, Xu C, Wang W, Cai S, Liang H, Yu H.
    Cancer Invest; 2024 Mar 15; 42(3):226-242. PubMed ID: 38616304
    [Abstract] [Full Text] [Related]

  • 3. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A.
    Ann Surg; 2022 Jan 01; 275(1):e229-e237. PubMed ID: 32398486
    [Abstract] [Full Text] [Related]

  • 4. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
    Tan Z, Lei Y, Xu J, Shi S, Hua J, Zhang B, Meng Q, Liu J, Zhang Y, Wei M, Yu X, Liang C.
    Aging (Albany NY); 2020 Nov 20; 12(23):24228-24241. PubMed ID: 33226369
    [Abstract] [Full Text] [Related]

  • 5. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, Baba H, Goel A.
    Gastroenterology; 2020 Aug 20; 159(2):562-574. PubMed ID: 32376411
    [Abstract] [Full Text] [Related]

  • 6. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
    Peng T, Sun F, Yang JC, Cai MH, Huai MX, Pan JX, Zhang FY, Xu LM.
    World J Gastroenterol; 2024 May 21; 30(19):2575-2602. PubMed ID: 38817665
    [Abstract] [Full Text] [Related]

  • 7. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
    Chen D, Huang H, Zang L, Gao W, Zhu H, Yu X.
    Front Immunol; 2021 May 21; 12():728062. PubMed ID: 34691034
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R, He Y, Zhang H, Wang J, Liu X, Liu H, Wu H, Liang Z.
    Front Immunol; 2021 May 21; 12():690056. PubMed ID: 34335594
    [Abstract] [Full Text] [Related]

  • 11. Unraveling pancreatic ductal adenocarcinoma immune prognostic signature through a naive B cell gene set.
    Zhang S, Ta N, Zhang S, Li S, Zhu X, Kong L, Gong X, Guo M, Liu Y.
    Cancer Lett; 2024 Jul 10; 594():216981. PubMed ID: 38795761
    [Abstract] [Full Text] [Related]

  • 12. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
    Yang B, Zhou M, Wu Y, Ma Y, Tan Q, Yuan W, Ma J.
    Front Immunol; 2021 Jul 10; 12():769047. PubMed ID: 34777388
    [Abstract] [Full Text] [Related]

  • 13. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
    Tan Z, Liu J, Xu J, Zhang B, Yu X, Wang W, Liang C.
    J Cancer Res Clin Oncol; 2023 Jul 10; 149(8):4853-4865. PubMed ID: 36269388
    [Abstract] [Full Text] [Related]

  • 14. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P, Maddipati R, Lim KH, Tozeren A.
    PLoS One; 2018 Jul 10; 13(8):e0201751. PubMed ID: 30092011
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Hu Y, Chen Y.
    Sci Rep; 2021 Sep 08; 11(1):17844. PubMed ID: 34497315
    [Abstract] [Full Text] [Related]

  • 17. Immune-related genes LAMA2 and IL1R1 correlate with tumor sites and predict poor survival in pancreatic adenocarcinoma.
    Zhang M, Zeng L, Peng Y, Fan B, Chen P, Liu J.
    Future Oncol; 2021 Aug 08; 17(23):3061-3076. PubMed ID: 34156282
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ, Liu L, Xu HX, Wu CT, Xiang JF, Xu J, Liu C, Long J, Ni QX, Yu XJ.
    Br J Surg; 2016 Aug 08; 103(9):1189-99. PubMed ID: 27256393
    [Abstract] [Full Text] [Related]

  • 20. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S.
    Gastroenterology; 2024 May 08; 166(5):859-871.e3. PubMed ID: 38280684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.